PER 34.1% 8.9¢ percheron therapeutics limited

anp chart, page-751

  1. 3,222 Posts.
    lightbulb Created with Sketch. 574
    in follow up to George re Biogen,

    ...and consequently, in the few days after this announcement from Biogen, over 4B USD was added to their market cap. (with only 330 people with the disease in the US) Meanwhile, Sarepta currently rake a billion in sales from just 30% of the DMD market with no real efficacy found from their drugs. And here we are under $100M MC.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.